J. Akkila

发表

Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol.

T. Honkanen, M. Karlsson, L. Lehtonen, 1997, Arzneimittel-Forschung.

Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.

M. Nieminen, S. Mattila, A. Kuitunen, 1998, European heart journal.

Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers

K. Någren, L. Voipio‐Pulkki, M. Saraste, 1997, Clinical pharmacology and therapeutics.

The effect of flaxseed supplementation in processed foods on serum fatty acids and enterolactone

H. Adlercreutz, I. Salminen, A. Aro, 2002, European Journal of Clinical Nutrition.

Pharmacodynamic Interactions of Levosimendan and Felodipine in Patients with Coronary Heart Disease

J. Eha, L. Lehtonen, Saila Antila, 2003, Cardiovascular Drugs and Therapy.

in patients with congestive heart failure Hemodynamic and neurohumoral effects of continuous infusion of levosimendan

M. Nieminen, W. Remme, G. Hasenfuss, 2011 .

The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.

M. Scheinin, A. Illi, A. Gordin, 1993, British journal of clinical pharmacology.

Safety of levosimendan and other calcium sensitizers.

L. Lehtonen, J. Akkila, P. Mills-Owens, 1995, Journal of cardiovascular pharmacology.

Haemodynamic dose-efficacy of levosimendan in healthy volunteers

M. Nieminen, S. Sundberg, J. Lilleberg, 2007, European Journal of Clinical Pharmacology.

Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function.

M. Viitasalo, L. Toivonen, L. Lehtonen, 2000, Journal of cardiovascular pharmacology.

Dorsal hand vein responses to the α₁-adrenoceptor agonist phenylephrine do not predict responses to the α₂-adrenoceptor agonist dexmedetomidine.

M. Scheinin, A. Snapir, J. Posti, 2011, European journal of pharmacology.

Soluble and membrane-bound catechol-O-methyltransferase in normal and malignant mammary gland.

P. Heikkilä, J. Tenhunen, I. Ulmanen, 1999, Cancer letters.

The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition

M. Scheinin, A. Gordin, S. Sundberg, 2004, European Journal of Clinical Pharmacology.

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

M. Nieminen, W. Remme, G. Hasenfuss, 2000, Journal of the American College of Cardiology.

Myocardial efficiency during levosimendan infusion in congestive heart failure

H. Iida, K. Någren, J. Knuuti, 2000, Clinical pharmacology and therapeutics.

Exercise hemodynamics and catecholamine metabolism after catechol‐O‐methyltransferase inhibition with nitecapone

M. Scheinin, S. Kaakkola, A. Gordin, 1990, Clinical pharmacology and therapeutics.

Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates.

I. Wiklund, P. Puska, A. Nissinen, 1991, Journal of clinical epidemiology.

Effect of Cardiotonic Drugs on Myocardial Oxygen Consumption and Efficiency as Assessed by 11C-Acetate and PET

L. Voipio‐Pulkki, M. Saraste, H. Ukkonen, 1995 .

Estimation of Power and Analysis of qPCR Data with Normal Mixed Models

J. Akkila, Éva Tas, A. Partanen, 2008 .